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INTRODUCTION
Adult-onset Still’ s disease (AOSD) is a systemic inflam-
matory disease, and its major clinical manifestations include
high spiking fever, typical skin rash, polyarthritis, and neu-
trophilic leukocytosis. The common minor features are sore
throat, serositis, lymphadenopathy, splenomegaly, liver dys-
function, and negative results for antinuclear antibodies
(ANA) and rheumatoid factor (RF) assay (1). Although the
pathogenesis of AOSD has been investigated from various
aspects including infection, immune reaction, genetic factor,
environmental factor, and pregnancy or hormonal effects, it
has not been clearly identified yet. 
Forty to eighty percent of patients with active stage AOSD
show increased titers of immunoglobulin (Ig), most of which
are IgG, and sometimes, detected as a form of immune com-
plex (IC) (2-4). Ig or IC may influence the expression of Fc
gamma receptors (Fc Rs) on the surface of phagocytic cells
such as monocytes, macrophages, natural killer (NK) cells,
and neutrophils. Administration of high-dosage intravenous
immunoglobulins (IVIG) may induce remission of active
AOSD by means of blocking Fc R or regulating humoral
immune response (5-6). Patients with AOSD also have high
serum levels of interleukin-6 (IL-6), interferon- (INF- ), and
tumor necrosis factor- (TNF- ). IL-6 induced by Fc R trig-
gering may stimulate the ferritin synthesis and B cell prolif-
eration, but the ferritin inhibits Ig production of B cells (7-
10). Previously, both the concentration of IL-6 and that of
serum ferritin have been shown to rise and fall depending on
the disease activities in juvenile chronic arthritis and AOSD
(11, 12). Nakatani et al. recently reported that in Kawasaki
disease, which has similar clinical features with AOSD in
part, high level of Fc R II and III expression on the surfaces
of neutrophils and monocytes at active state fell after IVIG
therapy (13). 
The polymorphisms of Fc RIIa-131R/H and IIIa-176V/F
were also revealed as genetic risk factors for systemic lupus
erythematosus (SLE), especially lupus nephritis, and as sus-
ceptibility and/or severity markers for SLE and rheumatoid
arthritis (RA) in distinct ethnic groups (14-19). Fc R poly-
morphism might be associated with AOSD by means of IC
handling, cytokine production, and binding ability to acute
phase reactants, such as C-reactive protein (CRP). We inves-
tigated whether the polymorphisms of Fc RIIa-131R/H and
IIIa-176V/F influence the development and clinical manifes-
tations of AOSD. 
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Association Between Fc R IIa and IIIa Polymorphism and Clinical
Manifestations in Korean Patients with Adult-Onset Still's Disease
High-dose intravenous immunoglobulins alter the disease activity of adult-onset
Still’ s disease (AOSD). Because activation status of Fc R is possibly dependent
on their genetic polymorphisms, we investigated whether the polymorphisms of
Fc R IIa and IIIa are risk factors, and affect the clinical features of AOSD. Genomic
DNA was extracted from 36 patients and from 197 healthy controls. Polymerase
chain reaction for Fc R IIa and IIIa using the allele-specific primers and direct
sequencing of Fc R IIIa polymorphic site were performed. The frequencies of
Fc R IIa/IIIa genotype between patients with AOSD and controls were not differ-
ent. The allelic frequencies of Fc R IIa/IIIa between patients with AOSD and con-
trols were not different, either. However, the Fc R IIa-R/R131 genotype was asso-
ciated with a higher concentration of hemoglobin (p=0.04) and stable liver func-
tion (p=0.009) than the other genotypes. The Fc R IIIa-F/F176 genotype was
associated with significantly lower titers of serum ferritin (p=0.025), and higher
serum albumin (p=0.037) and cholesterol (p=0.014) concentrations than the other
genotypes. This study suggest that the Fc R IIa and IIIa polymorphisms might
not be genetic risk factors for AOSD in Korean, but contribute to the activity of
disease. Fc R IIa-R/R131 and IIIa-F/F176 genotypes, low-binding genotypes for
IgG2a and G1, may have more protective effects in acute stage of the disease
than the other genotypes. 
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MATERIALS AND METHODS
Patients 
Thirty-six Korean patients with AOSD and 197 Korean
healthy controls were enrolled in this study. The patients were
recruited between May 1998 and July 1999 at the Hospital
for Rheumatic Diseases and Guri Hospital of Hanyang Uni-
versity. Diagnosis of AOSD was made by the criteria of Yama-
guchi et al. (1). We excluded patients with occult infections,
malignancy, or definite signs that fulfilled the criteria for
other rheumatic diseases. Clinical manifestations and labo-
ratory data at acute stage were collected by interview and
retrospective review of medical records. 
Disease duration was considered from initial clinical mani-
festation to September 1999. The clinical parameters includ-
ed high fever (>39℃), arthritis (involvement of 4 or less
joints for oligoarticular type and 5 or more joints for polyartic-
ular type), skin rash, weight loss (>10% for 6 months), lym-
phadenopathy, hepatomegaly, splenomegaly, and sore throat
in physical examination, serositis and renal involvement. The
laboratory variables at active stage of the disease included
the counts of leukocytes and platelets, hemoglobin level, the
serum concentrations of albumin, transaminase (ALT/AST),
cholesterol, and ferritin. We determined ANA by an indirect
immunofluorescence test using IT-1 cell and RF by neph-
elometry. We also classified the disease-course into 3 cate-
gories; the monocyclic-systemic type was defined as an ini-
tial, single bout of systemic disease of variable duration, fol-
lowed by systemic remission, and the polycyclic-systemic
type referred to 2 or more episodes of systemic disease. The
chronic destructive type referred to recurrent systemic man-
ifestations, followed by bony erosion and deformities.
Fc R IIa and IIIa genotyping
For genotyping of Fc R IIa and IIIa, DNA was isolated
from peripheral blood (Puregene kit, Gentra systems, Min-
neapolis, MN, U.S.A.). Polymerase chain reaction (PCR) was
performed using allele-specific primers (Bioneer Co, Ltd.,
Cheongwon, Korea). Pan-primer of Fc R IIa was 5′ -TCA AAG
TGA AAC AAC AGC CTG ACT AC-3′ . Allele-specific
primer of Fc R IIa-131R was 5′ -ATG GAA AAT CCC AGA
AAT TCT CAC G-3′ , and that of Fc R IIa-131H was 5′ -ATG
GAA AAT CCC AGA AAT TCT CAC A-3′ . Pan-primer of
Fc R IIIa was 5′ -TCA CAT ATTTAC AGA ATG GCA ATG
G-3′ . Allele-specific primer of Fc R IIIa-F176 was 5′ -TCT
CTG AAG ACA CAT TTC TAC TCC CTA A-3′ , and that
of Fc R IIIa-V176 was 5′ -TCT CTG AAG ACA CAT TTC
TAC TCC CTA C-3′ . The PCR was performed in a Gene Amp
system 9600 (Perkin Elmer Biosystem, Norwalk, CT, U.S.A.)
with 100 ng of genomic DNA, 10  M of each primer, 100
mM of Tris-HCl, 500 mM of KCl, 15 mM (for IIa) or 25 mM
(for IIIa) of MgCl2, 20 mM dNTPs, and 1 unit of Taq DNA
polymerase (Boeringer Mannheim Biochemicals, Germany)
in a 50  L reaction volume. For Fc R IIa, PCR was started
with 94℃ for 5 min, 62℃ for 30 sec, and 72℃ for 3 min,
followed by 35 cycles of 94℃ for 45 sec, 62℃ for 30 sec,
72℃ for 45 sec, and ended with an extension step at 72℃for
10 min. For Fc R IIIa, PCR was started with 94℃for 5 min,
62℃ for 30 sec, and 72℃ for 3 min, followed by 35 cycles
of 94℃ for 30 sec, 55℃ for 30 sec, 72℃ for 30 sec, and
ended with an extension step at 72℃for 7 min. Fifteen micro-
liters of each amplified PCR product was analyzed by gel elec-
trophoresis for 40 min (100 V) on 2% agarose gel containing
ethidium bromide. The appearance of 378 (Fc R IIa) or 138
(Fc R IIIa) base pair PCR product in each allele-specific reac-
tion indicate the presence of the allele (15-18). 
Sequencing of Fc R IIIa genomic DNA 
Direct sequencing was performed to confirm the Fc R IIIa
genomic sequences for the samples that did not produce defini-
tive patterns on PCR. We amplified a portion of exon 4 that
corresponds to the second extracellular Ig-like domain (EC2).
The forward primer was 5′ -TGT AAA ACG ACG GCC AGT
TCA TCA TAA TTC TGT CTT CT-3′ , corresponding to nt
486-505. The reverse primer was 5′ -CAG GAA ACA GCT
ATG ACC CTT GAG TGA TGG TGA TGT TCA-3′ . The
size of the PCR product containing the nt 559 polymorphic
site was 162 bp. 
Fc R IIIa PCR products for sequencing were clarified with
2% agarose gel electrophoresis, and the products were puri-
fied with Qiaquick PCR clean-up kit (Qiagen, Germany).
Using ABI Prism BigDyeTM Terminator Cycle Sequencing
Ready Reaction Kits (PE Biosystem, CA, U.S.A.), the puri-
fied product was prepared for sequencing. The PCR for Big-
DyeTM adhesion to the purified PCR products was performed
by 25 cycles of 96℃ for 30 sec, 50℃ for 15 sec, and 60℃
for 4 min followed by an addition of 2  L of 3 M Na acetate
(pH 4.6) and 50  L of 95% ethanol. The samples were mixed
carefully and incubated on ice for 10 min. The mixture was
then centrifuged for 30 min at 12,000×g, followed by wash-
ing with 70% ethanol. The product was resuspended in 25
L of templates suppression reagent (supplied with Ready
Reaction Kits), heated at 95℃for 2 min, then chilled on ice.
The samples were read with ABI Prism 310 Genetic Ana-
lyzer (PE Biosystem, CA, U.S.A.).
Statistical analysis
The distribution of Fc R IIa and IIIa genotypes between 2
groups (AOSD patients vs. healthy controls) was compared
using the Chi-square test (2×2, 2×3 contingency table). A
probability of 0.05 (two-tailed) was used to reject the hypoth-
esis that there was no significant difference in the distribu-
tion of genotypes between the groups.  2 test was also used
to compare the frequency of Fc R IIa-R/R131 (2×2, 2×3Fc R IIa and IIIa Polymorphisms in Adult-onset Still’ s Disease 77
contingency table: R/R131 vs. R/H131 and/or H/H131)
and Fc R IIIa-F/F176 (F/F176 vs. V/F176 and/or V/V176),
and alleles (R131 vs. H131, F176 vs. V176) in each group.
The odds ratios (OR) and 95% confidence interval (95% CI)
were calculated to provide an estimate of the risk of AOSD in
Fc R IIa and IIIa genotypes or allotype compared with the
disease-free controls. The clinical parameters or laboratory
variables at active stage of disease were compared using inde-
pendent sample t-test or ANOVA. We used SPSS version 8.0
for Windows for the statistical analysis. 
RESULTS
Clinical features of patients with AOSD
Of the 36 patients with AOSD, 4 were men and 32 were
women. The mean age at diagnosis was 31.3±10.4 yr, the
mean duration from initial manifestation to diagnosis was
20.0±16.5 months, and the duration of follow-up was 33.6
±26.1 months. There was no significant difference between
the two sexes. During the disease course, 15 patients were
classified as oligoarticular type, 16 as polyarticular type, and
3 had no arthritis. Two patients could not be classified because
of short disease duration (Table 1). The frequency of clinical
features were as follows: high fever 97.2%, arthritis 88.9%,
skin rash 88.9%, sore throat 55.6%, hepatomegaly 44.4%,
lymphadenopathy 41.7%, splenomegaly 33.3%, serositis
27.8%, renal involvement 13.9%, and weight loss 13.9%.
The mean values of laboratory data at the time of active dis-
ease were as follows; leukocyte 17,294/ L, platelet 429,694/
L, hemoglobin 9.5 g/dL, erythrocyte sedimentation rate 55
mm/hr (Wintrobe method), C-reactive protein 7.8 mg/dL
(normal <0.8 mg/dL), serum ferritin 4,986 ng/dL, serum albu-
min 3.6 g/dL, and serum cholesterol 182 mg/dL. Positive re-
sults of ANA and RF were found in 30.6% and 19.4%, respec-
tively, at very low titers.
The distribution of Fc R IIa and IIIa genotypes, and its
relationship with clinical features
The Fc R IIa and IIIa genotypes and alleles did not show a
significant difference between patients with AOSD and healthy
Age at diagnosis (yr) 31.3±10.4
Duration of diagnosis (months) 20.0±16.5
Sex (M/F) 4/32
Follow-up duration (months) 33.6±26.1
Disease course: No. of patients
Monocyclic-systemic type 7
Oligoarticular type 5
Polyarticular type 1
Polycyclic-systemic type 24
Oligoarticular type 9
Polyarticular type 11
Chronic destructive type 5
Oligoarticular type 1
Polyarticular type 4
AOSD patients (n=36)
Table 1. Characteristics of patients with AOSD and healthy
controls
Healthy controls (n=197) were consisted of 99 males and 98 females.
*3 cases had no arthritis, and 2 cases could not be classified due to
the short duration of follow-up.
Genotype no. (%)
IIa-131R/R 4 (11%) 16 (8%)
IIa-131R/H 17 (47%) 99 (50%)
IIa-131H/H 15 (42%) 82 (42%)
IIIa-176V/V 3 (8%) 22 (11%)
IIIa-176V/F 22 (61%) 104 (53%)
IIIa-176F/F 11 (31%) 71 (36%)
Allele frequencies
IIa-131R 0.347 0.331
IIa-131H 0.653 0.669
IIIa-176V 0.389 0.378
IIIa-176F 0.611 0.622
Fc R IIa & IIIa
AOSD patients 
(n=36)
Healthy controls*
(n=197)
Table 2. Distribution of Fc R IIa and IIIa genotypes and alle-
les in AOSD and healthy controls
Leukocytes (×10
3/L) 17,294±7,377 23,900±11,625 16,499±5,493 16,433±7,654
Hemogloblin (g/dL) * 9.5±1.8 11.2±1.6 9.3±2.0 9.2±1.4
Platelets(×10
3/L) 429,694±135,523 454,750±198,807 431,882±157,602 420,533±93,732
ESR (mm/hr) 55.2±21.4 40.5±24.4 53.5±21.2 61±20
CRP (mg/dL) 7.8±5.0 3.9±4.1 8.1±4.7 8.6±5.5
Serum albumin (mg/dL) 3.6±0.6 4.0±0.4 3.5±0.6 3.7±0.6
ALT (unit) 93±123 38±32 88±93 113±163
AST (unit)
� 70±77 33±86 2 ±75 88±88
Serum cholesterol (mg/dL) 182±51 187±51 189±58 172±45
Serum ferritin (ng/dL) 4,986±6,968 3,310±4,116 7,209±9,235 2,914±2,977
Table 3. Relationship between laboratory data and Fc R IIa genotypes in patients with AOSD
Patients (n=36) Fc R IIa-R/R Fc R IIa-R/H Fc R IIa-H/H
*p=0.009 IIa-RR vs. IIa-RH/HH genotype, 
� p=0.04 IIa-RR vs. IIa-RH/HH genotype. 
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Leukocytes (×10
3/L) 17,294±7,377 14,633±1,159 17,504±5,474 17,599±11,178
Hemogloblin (g/dL) 9.5±1.8 9.6±1.9 9.4±1.9 9.5±1.8
Platelets (×10
3/L) 429,694±135,523 521,000±170,853 423,681±127,404 416,828±146,954
ESR (mm/hr) 55±21 54±95 7 ±21 52±26
CRP (mg/dL) 7.8±5.0 7.0±0.7 8.0±4.6 7.7±6.6
Serum albumin (mg/dL)* 3.6±0.6 3.7±0.3 3.4±0.5 3.9±0.7
ALT (unit) 93±123 21±9.0 95±89 108±187
AST (unit) 70±77 32±11 76±76.8 67±89
Serum cholesterol (mg/dL)
� 182±51 151±51 181±46 192±64
Serum ferritin (ng/dL)
� 4,986±6,968 3,114±2,573 6,660±8,381 2,147±2,240
Table 4. Relationship between laboratory data and Fc R IIIa genotype in AOSD
Patients (n=36) Fc R IIIa-V/V Fc R IIIa-V/F Fc R IIIa-F/F
*p=0.037 IIIa-FF vs. IIIa-VV/VF genotype, 
� p=0.014 IIIa-VV vs. IIIa-VF/FF genotype, 
� p=0.025 IIIa-FF vs. IIIa-VV/VF genotype.
Values are expressed as mean±standard deviation
controls (Table 2). There was no significant difference between
Fc R IIa and IIIa alleles and the clinical parameters (data not
shown). The patients with AOSD with the Fc R IIa-R/R131
genotype showed significantly higher concentrations of hemo-
globin (p=0.009), and lower concentrations of serum AST
(p=0.04) than those with the Fc R IIa-RH/HH genotype
(Table 3). The Fc R IIIa-F/F176 genotype was also revealed
to be associated with significantly lower titers of serum fer-
ritin (p=0.025), and higher serum albumin (p=0.037) and
cholesterol (p=0.014) concentrations than the other genotypes
(Table 4). 
The patients with polyarticular type showed lower concen-
trations of serum albumin (p=0.025, 3.4±0.5 vs. 3.9±0.6),
higher concentrations of serum ferritin (p=0.078, 7,179±
8,907 vs. 2,628±2,858) than those with oligoarticular type.
During the disease course, patients with the polycyclic-sys-
temic type revealed higher titers of serum ferritin (p=0.013,
6,657±8,135 vs. 1,735±1,994) than those with the mono-
cyclic-systemic type. The patients with the chronic destruc-
tive type marked higher platelet counts (p=0.001, 618,750
±134,772 vs. 380,326±94,522), and were much more ane-
mic (p=0.04, 8.3±1.2 vs.10.3±1.5) than the other two types.
However we could not find any statistically significant cor-
relation between the genotypes and the clinical course due to
the small number of patients in each group.
DISCUSSION
Fc Rs play important roles in immune regulation, as they
link antibody-mediated immune responses with cellular effec-
tor function. Fc Rs have three distinct types: Fc RI, Fc RII,
and Fc RIII, with different IgG binding affinities and IgG
subclass specificities (20). The structural heterogeneity of Fc R
is reflected in a wide range of biologic activities, including
phagocytosis, antibody-dependent cell-mediated cytotoxici-
ty, and release of inflammatory mediator, as well as clearance
of antigen/antibody immune complex and regulation of anti-
body production (21). Additional diversity of individual Fc
receptor-mediated function is related to genetically determined
polymorphisms (21). Fc R IIa alleles (R131 and H131) differ
in their capacity to bind IgG2, and Fc R IIIa alleles (V176
and F176) differ in IgG1 and IgG3 binding. In some ethnic
populations with lupus, Fc R IIa-R131 and Fc R IIIa-F176,
the alleles with a lower binding capacity, were known to be
associated with nephritis, whereas Fc R IIa-H131 and Fc R
IIIa-V176, the alleles with a high binding capacity, seemed
to be protective (14-17, 22, 23).
Although the pathogenesis of AOSD has not been clearly
defined, we speculate that Fc Rs may play a role in the patho-
genesis based on the following evidences.
First, the IVIG treatment was effective in steroid-resistant
cases of AOSD (5, 24, 25). The mechanism of action could be
IVIG-mediated Fc receptor blockage and modulation. IVIG
bound to the Fc R on the surface of B cell induce apoptosis
and inhibit the production of Ig or B cell proliferation (26).
In the acute stage of Kawasaki disease, which has similar clini-
cal manifestations with AOSD, the expression of Fc R II and
III was modulated by the infusion of IVIG (13, 27). These
findings suggest that the immune system in patients with
AOSD could be regulated by modulation of Fc R II and III.
Second, 40% to 80% of patients with AOSD have increased
IgG level, sometimes in a form of IC (2-4). The abundant IgG
in AOSD might bind to auto-antigens or to foreign antigens
and then, induce Fc R-mediated immune reactions. Third,
AOSD patients in active stage had increased concentrations
of IL-6, TNF- , or INF- (11). Fc R ligation may trigger the
release of IL-1, IL-6, and TNF- (8, 28). Fc R IIIa ligation of
human macrophages in RA patients induces production of
both TNF- and IL-1 by immune complexes containing IgG
RF (29). Fc R IIIa engagement on the NK cells from V/V
high-binding homozygotes led to a larger rise in the concen-
tration of Ca++ influx ([Ca++]i), a greater level of NK cell acti-
vation, and a more rapid induction of activation-induced cell
death than F/F low-binding homozygotes (16). Fc R IIa is a
receptor for C-reactive protein on human monocytes and poly-
morphonuclear leukocytes. Fc R IIa R-131 homozygote binds
CRP with a higher affinity and initiates higher increase inFc R IIa and IIIa Polymorphisms in Adult-onset Still’ s Disease 79
[Ca++]i (30) than Fc R IIa H-131 homozygote. Therefore, the
production of proinflammatory cytokines and activation of
cells in AOSD may be influenced by Fc R polymorphisms.
Fourth, the serum ferritin concentration in active AOSD was
also significantly higher than that in inactive AOSD (31).
Ferritin has an inhibitory effect on the in vitro proliferation
of T lymphocytes and on the differentiation of human B lym-
phocytes (10). IL-6 increased the transferrin uptake and pro-
duction of ferritin (32). TNF, which can be induced by Fc R
ligation, may also stimulate the ferritin synthesis (7). Collec-
tively, Fc R polymorphism may influence the serum concen-
tration of ferritin through the cytokine-mediated inflamma-
tory pathway.
Although this study was too underpowered to test the hypo-
thesis due to small sample size, Fc R IIa-R/H131 and IIIa-V/
F176 polymorphisms might not be genetic risk factors for
AOSD. However, Fc R IIa-R/R131 genotype was associated
with a higher hemoglobin concentration and lower serum
transaminase concentration, and Fc R IIIa-F/F176 was asso-
ciated with a higher concentration of serum albumin and a
lower concentration of serum ferritin than the other two geno-
types. These data suggest that Fc R IIa-R/R131 and Fc R IIIa-
F/F176 genotypes could be protective during the active stage
of AOSD, and the difference in cell activation induced by
the Fc R polymorphism may influence the concentration of
ferritin and albumin, which reflect the level of cytokine release
according to the Fc R polymorphisms. The patients with the
Fc R IIIa-V/V176 genotype had a higher titer of serum fer-
ritin, which has been known as a marker of disease activity in
AOSD, and a lower concentration of serum albumin in the
acute stage. These findings are consistent with our previous
clinical report (2), which emphasized that the patients with
lower concentrations of serum albumin in the early stage had
a recurrent and chronic disease course. However, we could not
find any difference in the clinical course by the Fc R polymor-
phism due to the small number of patients in each group.
Fc R polymorphism may affect the level of activation of phago-
cytic cells in AOSD, whereas it contributes to the lupus patho-
genesis as a genetic risk factor by the different capacity to han-
dle IgG-containing immune complex. 
In conclusion, there was no significant skewing in the dis-
tribution of the Fc R IIa and IIIa genotypes and alleles between
the patients with AOSD and disease-free controls. However,
Fc R IIa and IIIa polymorphisms might contribute to the
process of active disease. Fc R IIa-R/R131 and IIIa-F/F176
genotypes or alleles may provide more protective effects in
acute stage of the disease than the other genotypes. There-
fore, compared with the defective scavenging of IC in SLE,
especially lupus nephritis, Fc R IIa and IIIa polymorphism
may affect the effector cell activation via Fc R triggered by IG
or IC in AOSD. It will be valuable to assess the relationship
between AOSD and Fc R polymorphism with more AOSD
patients to confirm our observation. 
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